Davis C Ryman1, Natalia Acosta-Baena2, Paul S Aisen2, Thomas Bird2, Adrian Danek2, Nick C Fox2, Alison Goate2, Peter Frommelt2, Bernardino Ghetti2, Jessica B S Langbaum2, Francisco Lopera2, Ralph Martins2, Colin L Masters2, Richard P Mayeux2, Eric McDade2, Sonia Moreno2, Eric M Reiman2, John M Ringman2, Steve Salloway2, Peter R Schofield2, Reisa Sperling2, Pierre N Tariot2, Chengjie Xiong2, John C Morris2, Randall J Bateman2. 1. From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universität Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medellín, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston. rymand@neuro.wustl.edu batemanr@neuro.wustl.edu. 2. From the Departments of Neurology (D.C.R., J.C.M., R.J.B.), Biostatistics (C.X.), and Psychiatry (A.G.), Washington University School of Medicine, St. Louis, MO; Neurologische Klinik Ludwig-Maximilians-Universität Munich and German Center for Neurodegenerative Diseases (A.D.), Munich, Germany; Department of Neurosciences (P.S.A.), University of California San Diego; Mental Health Research Institute (C.L.M.), University of Melbourne, Australia; Grupo de Neurociencias de Antioquia (N.A.-B., F.L., S.M.), Universidad de Antioquia, Medellín, Colombia; Department of Neurology (E.M.), University of Pittsburgh, PA; Department of Neurology (T.B.), University of Washington, Seattle; Banner Alzheimer's Institute (J.B.S.L., E.M.R., P.N.T.), Phoenix, AZ; Neuroscience Research Australia and University of New South Wales (P.R.S.), Sydney, Australia; Edith Cowan University (R.M.), Western Australia; Easton Center for Alzheimer's Disease Research at UCLA (J.M.R.), Los Angeles, CA; Department of Neurology (R.P.M.), Columbia University, New York, NY; Queen Square Institute of Neurology (N.C.F.), University College London; Department of Neurology (S.S.), Warren Alpert Medical School, Brown University, Providence, RI; and Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Boston.
Abstract
OBJECTIVE: To identify factors influencing age at symptom onset and disease course in autosomal dominant Alzheimer disease (ADAD), and develop evidence-based criteria for predicting symptom onset in ADAD. METHODS: We have collected individual-level data on ages at symptom onset and death from 387 ADAD pedigrees, compiled from 137 peer-reviewed publications, the Dominantly Inherited Alzheimer Network (DIAN) database, and 2 large kindreds of Colombian (PSEN1 E280A) and Volga German (PSEN2 N141I) ancestry. Our combined dataset includes 3,275 individuals, of whom 1,307 were affected by ADAD with known age at symptom onset. We assessed the relative contributions of several factors in influencing age at onset, including parental age at onset, age at onset by mutation type and family, and APOE genotype and sex. We additionally performed survival analysis using data on symptom onset collected from 183 ADAD mutation carriers followed longitudinally in the DIAN Study. RESULTS: We report summary statistics on age at onset and disease course for 174 ADAD mutations, and discover strong and highly significant (p < 10(-16), r2 > 0.38) correlations between individual age at symptom onset and predicted values based on parental age at onset and mean ages at onset by mutation type and family, which persist after controlling for APOE genotype and sex. CONCLUSIONS: Significant proportions of the observed variance in age at symptom onset in ADAD can be explained by family history and mutation type, providing empirical support for use of these data to estimate onset in clinical research.
OBJECTIVE: To identify factors influencing age at symptom onset and disease course in autosomal dominant Alzheimer disease (ADAD), and develop evidence-based criteria for predicting symptom onset in ADAD. METHODS: We have collected individual-level data on ages at symptom onset and death from 387 ADAD pedigrees, compiled from 137 peer-reviewed publications, the Dominantly Inherited Alzheimer Network (DIAN) database, and 2 large kindreds of Colombian (PSEN1E280A) and Volga German (PSEN2N141I) ancestry. Our combined dataset includes 3,275 individuals, of whom 1,307 were affected by ADAD with known age at symptom onset. We assessed the relative contributions of several factors in influencing age at onset, including parental age at onset, age at onset by mutation type and family, and APOE genotype and sex. We additionally performed survival analysis using data on symptom onset collected from 183 ADAD mutation carriers followed longitudinally in the DIAN Study. RESULTS: We report summary statistics on age at onset and disease course for 174 ADAD mutations, and discover strong and highly significant (p < 10(-16), r2 > 0.38) correlations between individual age at symptom onset and predicted values based on parental age at onset and mean ages at onset by mutation type and family, which persist after controlling for APOE genotype and sex. CONCLUSIONS: Significant proportions of the observed variance in age at symptom onset in ADAD can be explained by family history and mutation type, providing empirical support for use of these data to estimate onset in clinical research.
Authors: Eric M Reiman; Jessica B S Langbaum; Adam S Fleisher; Richard J Caselli; Kewei Chen; Napatkamon Ayutyanont; Yakeel T Quiroz; Kenneth S Kosik; Francisco Lopera; Pierre N Tariot Journal: J Alzheimers Dis Date: 2011 Impact factor: 4.472
Authors: John C Morris; Paul S Aisen; Randall J Bateman; Tammie L S Benzinger; Nigel J Cairns; Anne M Fagan; Bernardino Ghetti; Alison M Goate; David M Holtzman; William E Klunk; Eric McDade; Daniel S Marcus; Ralph N Martins; Colin L Masters; Richard Mayeux; Angela Oliver; Kimberly Quaid; John M Ringman; Martin N Rossor; Stephen Salloway; Peter R Schofield; Natalie J Selsor; Reisa A Sperling; Michael W Weiner; Chengjie Xiong; Krista L Moulder; Virginia D Buckles Journal: Clin Investig (Lond) Date: 2012-10-01
Authors: L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn Journal: JAMA Date: 1997 Oct 22-29 Impact factor: 56.272
Authors: Randall J Bateman; Paul S Aisen; Bart De Strooper; Nick C Fox; Cynthia A Lemere; John M Ringman; Stephen Salloway; Reisa A Sperling; Manfred Windisch; Chengjie Xiong Journal: Alzheimers Res Ther Date: 2011-01-06 Impact factor: 6.982
Authors: Sigrun Roeber; Felix Müller-Sarnowski; Julia Kress; Dieter Edbauer; Tanja Kuhlmann; Frank Tüttelmann; Christoph Schindler; Pia Winter; Thomas Arzberger; Ulrich Müller; Adrian Danek; Hans A Kretzschmar Journal: J Neural Transm (Vienna) Date: 2015-09-08 Impact factor: 3.575
Authors: Eric McDade; Guoqiao Wang; Brian A Gordon; Jason Hassenstab; Tammie L S Benzinger; Virginia Buckles; Anne M Fagan; David M Holtzman; Nigel J Cairns; Alison M Goate; Daniel S Marcus; John C Morris; Katrina Paumier; Chengjie Xiong; Ricardo Allegri; Sarah B Berman; William Klunk; James Noble; John Ringman; Bernardino Ghetti; Martin Farlow; Reisa A Sperling; Jasmeer Chhatwal; Stephen Salloway; Neill R Graff-Radford; Peter R Schofield; Colin Masters; Martin N Rossor; Nick C Fox; Johannes Levin; Mathias Jucker; Randall J Bateman Journal: Neurology Date: 2018-09-14 Impact factor: 9.910
Authors: Bruce W Patterson; Donald L Elbert; Kwasi G Mawuenyega; Tom Kasten; Vitaliy Ovod; Shengmei Ma; Chengjie Xiong; Robert Chott; Kevin Yarasheski; Wendy Sigurdson; Lily Zhang; Alison Goate; Tammie Benzinger; John C Morris; David Holtzman; Randall J Bateman Journal: Ann Neurol Date: 2015-07-20 Impact factor: 10.422
Authors: Diego Castillo-Barnes; Li Su; Javier Ramírez; Diego Salas-Gonzalez; Francisco J Martinez-Murcia; Ignacio A Illan; Fermin Segovia; Andres Ortiz; Carlos Cruchaga; Martin R Farlow; Chengjie Xiong; Neil R Graff-Radford; Peter R Schofield; Colin L Masters; Stephen Salloway; Mathias Jucker; Hiroshi Mori; Johannes Levin; Juan M Gorriz Journal: Inf Fusion Date: 2020-01-07 Impact factor: 12.975
Authors: Yen Ying Lim; Jason Hassenstab; Carlos Cruchaga; Alison Goate; Anne M Fagan; Tammie L S Benzinger; Paul Maruff; Peter J Snyder; Colin L Masters; Ricardo Allegri; Jasmeer Chhatwal; Martin R Farlow; Neill R Graff-Radford; Christoph Laske; Johannes Levin; Eric McDade; John M Ringman; Martin Rossor; Stephen Salloway; Peter R Schofield; David M Holtzman; John C Morris; Randall J Bateman Journal: Brain Date: 2016-08-12 Impact factor: 13.501